FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3143433495> ?p ?o ?g. }

• W3143433495 abstract "This phase 1-2 study evaluated brentuximab vedotin (BV) combined with nivolumab (Nivo) as first salvage therapy in patients with relapsed/refractory (r/r) classical Hodgkin lymphoma (cHL). In parts 1 and 2, patients received staggered dosing of BV and Nivo in cycle 1, followed by same-day dosing in cycles 2 to 4. In part 3, both study drugs were dosed, same day, for all 4 cycles. At end of study treatment, patients could undergo autologous stem cell transplantation (ASCT) per investigator discretion. The objective response rate (ORR; N = 91) was 85%, with 67% achieving a complete response (CR). At a median follow-up of 34.3 months, the estimated progression-free survival (PFS) rate at 3 years was 77% (95% confidence interval [CI], 65% to 86%) and 91% (95% CI, 79% to 96%) for patients undergoing ASCT directly after study treatment. Overall survival at 3 years was 93% (95% CI, 85% to 97%). The most common adverse events (AEs) prior to ASCT were nausea (52%) and infusion-related reactions (43%), all grade 1 or 2. A total of 16 patients (18%) had immune-related AEs that required systemic corticosteroid treatment. Peripheral blood immune signatures were consistent with an activated T-cell response. Median gene expression of CD30 in tumors was higher in patients who responded compared with those who did not. Longer-term follow-up of BV and Nivo as a first salvage regimen shows durable efficacy and impressive PFS, especially in patients who proceeded directly to transplant, without additional toxicity concerns. This trial was registered at www.clinicaltrials.gov as #NCT02572167." @default.
• W3143433495 created "2021-04-13" @default.
• W3143433495 creator A5001102192 @default.
• W3143433495 creator A5005446802 @default.
• W3143433495 creator A5010044749 @default.
• W3143433495 creator A5013717203 @default.
• W3143433495 creator A5030788778 @default.
• W3143433495 creator A5035163326 @default.
• W3143433495 creator A5052260087 @default.
• W3143433495 creator A5052962596 @default.
• W3143433495 creator A5058829071 @default.
• W3143433495 creator A5059729547 @default.
• W3143433495 creator A5060314041 @default.
• W3143433495 creator A5062879857 @default.
• W3143433495 creator A5078307926 @default.
• W3143433495 creator A5078434670 @default.
• W3143433495 creator A5080373697 @default.
• W3143433495 creator A5085801543 @default.
• W3143433495 creator A5088169139 @default.
• W3143433495 date "2021-08-12" @default.
• W3143433495 modified "2023-10-10" @default.
• W3143433495 title "Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results." @default.
• W3143433495 cites W1978849352 @default.
• W3143433495 cites W2034218339 @default.
• W3143433495 cites W2037994583 @default.
• W3143433495 cites W2039888190 @default.
• W3143433495 cites W2111070506 @default.
• W3143433495 cites W2112001172 @default.
• W3143433495 cites W2119147717 @default.
• W3143433495 cites W2137591261 @default.
• W3143433495 cites W2155256323 @default.
• W3143433495 cites W2159746531 @default.
• W3143433495 cites W2316159879 @default.
• W3143433495 cites W2340968189 @default.
• W3143433495 cites W2463754429 @default.
• W3143433495 cites W2495609140 @default.
• W3143433495 cites W2504623699 @default.
• W3143433495 cites W2514468425 @default.
• W3143433495 cites W2593533764 @default.
• W3143433495 cites W2596050027 @default.
• W3143433495 cites W2751498226 @default.
• W3143433495 cites W2772084440 @default.
• W3143433495 cites W2780959327 @default.
• W3143433495 cites W2803000479 @default.
• W3143433495 cites W2883336386 @default.
• W3143433495 cites W2898828813 @default.
• W3143433495 cites W2908920184 @default.
• W3143433495 cites W2993070286 @default.
• W3143433495 cites W3080277143 @default.
• W3143433495 cites W4238273412 @default.
• W3143433495 cites W950004053 @default.
• W3143433495 doi "https://doi.org/10.1182/blood.2020009178" @default.
• W3143433495 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33827139" @default.
• W3143433495 hasPublicationYear "2021" @default.
• W3143433495 type Work @default.
• W3143433495 sameAs 3143433495 @default.
• W3143433495 citedByCount "80" @default.
• W3143433495 countsByYear W31434334952021 @default.
• W3143433495 countsByYear W31434334952022 @default.
• W3143433495 countsByYear W31434334952023 @default.
• W3143433495 crossrefType "journal-article" @default.
• W3143433495 hasAuthorship W3143433495A5001102192 @default.
• W3143433495 hasAuthorship W3143433495A5005446802 @default.
• W3143433495 hasAuthorship W3143433495A5010044749 @default.
• W3143433495 hasAuthorship W3143433495A5013717203 @default.
• W3143433495 hasAuthorship W3143433495A5030788778 @default.
• W3143433495 hasAuthorship W3143433495A5035163326 @default.
• W3143433495 hasAuthorship W3143433495A5052260087 @default.
• W3143433495 hasAuthorship W3143433495A5052962596 @default.
• W3143433495 hasAuthorship W3143433495A5058829071 @default.
• W3143433495 hasAuthorship W3143433495A5059729547 @default.
• W3143433495 hasAuthorship W3143433495A5060314041 @default.
• W3143433495 hasAuthorship W3143433495A5062879857 @default.
• W3143433495 hasAuthorship W3143433495A5078307926 @default.
• W3143433495 hasAuthorship W3143433495A5078434670 @default.
• W3143433495 hasAuthorship W3143433495A5080373697 @default.
• W3143433495 hasAuthorship W3143433495A5085801543 @default.
• W3143433495 hasAuthorship W3143433495A5088169139 @default.
• W3143433495 hasBestOaLocation W31434334951 @default.
• W3143433495 hasConcept C121332964 @default.
• W3143433495 hasConcept C121608353 @default.
• W3143433495 hasConcept C126322002 @default.
• W3143433495 hasConcept C141071460 @default.
• W3143433495 hasConcept C142424586 @default.
• W3143433495 hasConcept C143998085 @default.
• W3143433495 hasConcept C197934379 @default.
• W3143433495 hasConcept C2776694085 @default.
• W3143433495 hasConcept C2777701055 @default.
• W3143433495 hasConcept C2778191690 @default.
• W3143433495 hasConcept C2778336483 @default.
• W3143433495 hasConcept C2779338263 @default.
• W3143433495 hasConcept C2780030458 @default.
• W3143433495 hasConcept C2780580376 @default.
• W3143433495 hasConcept C2780775027 @default.
• W3143433495 hasConcept C2781413609 @default.
• W3143433495 hasConcept C2992779791 @default.
• W3143433495 hasConcept C71924100 @default.
• W3143433495 hasConcept C87355193 @default.
• W3143433495 hasConcept C90924648 @default.
• W3143433495 hasConceptScore W3143433495C121332964 @default.

• next